Compare AVLN & VYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AVLN | VYX |
|---|---|---|
| Founded | N/A | 1881 |
| Country | United States | United States |
| Employees | N/A | 13500 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2026 | N/A |
| Metric | AVLN | VYX |
|---|---|---|
| Price | $28.73 | $8.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $13.67 |
| AVG Volume (30 Days) | 258.9K | ★ 1.9M |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $24.90 | $6.02 |
| 52 Week High | $33.32 | $13.82 |
| Indicator | AVLN | VYX |
|---|---|---|
| Relative Strength Index (RSI) | 43.91 | 54.67 |
| Support Level | $26.68 | $7.52 |
| Resistance Level | $29.59 | $8.63 |
| Average True Range (ATR) | 1.99 | 0.37 |
| MACD | 0.19 | 0.00 |
| Stochastic Oscillator | 61.44 | 62.37 |
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
NCR Voyix Corp is a company providing services of digital commerce solutions for retail, restaurant, and digital banking. The company operates in two reportable segments: Retail, and Restaurants. The Retail segment provides software solutions for retailers of all sizes, enhancing operational efficiency and customer experience. The Restaurants segment offers end-to-end technology solutions for food service establishments, improving operational efficiency, and customer satisfaction, and reducing costs. The company derives maximum revenue from Retail segment. Geographically, the company operates in United States, Americas (excluding United States), Europe, Middle East and Africa, and Asia Pacific. It derives maximum revenue from United States.